Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

This study has been completed.
Information provided by (Responsible Party):
EMD Serono Identifier:
First received: March 3, 2008
Last updated: October 21, 2013
Last verified: October 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2011
  Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Smith, D., P. Conkling, D. Richards, C. Alemany, T. Boyd, L. Garbo, D. Loesch, D. Wages, A. Bexon, J. Murphy. Phase 1 Study of the Toll-like Receptor (TLR9) Agonist, IMO-2055, Combined with Erlotinib and Bevacizumab in Patients with Advanced or Metastatic non-Small Cell Lung Cancer. ECCO-ESMO Annual Meeting, 2009. Abstract 9.148.